A Pase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (anti-PDL1) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
April 26, 2019
End Date
April 14, 2024
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
April 26, 2019
End Date
April 14, 2024